J

    Jupiter Neurosciences, Inc. Common Stock (JUNS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.54
    -0.64 (-15.31%)

    Market Cap: $4.67M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(3/7)
    Avg Surprise
    -1271.66%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 14
    		$-5.06N/AN/ABeat-7128.6%
    Mar 26
    Reported Apr 1
    		$-4.39$-0.05-8672.80%Miss-8672.8%
    Dec 25
    Reported Feb 25
    		$-0.07$-0.06-24.67%Miss-49.6%
    Sep 25
    Reported Nov 14
    		$-0.07$-0.08+12.50%Beat-250.0%
    Jun 25
    Reported Aug 18
    		$-0.07$-0.07+0.00%Beat+0.0%
    Mar 25
    Reported May 15
    		$-0.05$-0.03-66.67%Miss-66.7%
    Dec 24
    Reported Mar 28
    		$-0.05$-0.02-150.00%Miss-
    Sep 24
    Reported Dec 23
    		$-0.02$-0.02+0.00%Beat-
    Dec 21
    Reported Mar 30
    		$-0.07$0.00N/AMiss-
    Sep 21
    Reported Nov 9
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.37EV/EBITDAN/A
    Price/FCF-0.38xFCF Yield-265.93%
    Profitability
    Profit Margin0.00%Operating Margin-11313.00%
    ROE-1889.00%ROIC-606.96%
    Financial Health
    Debt/Equity-4.18xInterest Coverage-32.73x
    Current Ratio0.66xQuick Ratio0.62x
    Trading Statistics
    BetaN/AAvg Volume3.75M
    52-Week High$137.9652-Week Low$2.88

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.97
    SMA 20$5.25
    SMA 50$10.19
    SMA 200$38.28
    EMA 10$4.84
    EMA 20$5.81
    EMA 50$9.89
    EMA 200$33.70

    MACD

    Line: -1.56Signal: -1.77Hist: 0.21

    ADX

    ADX: 55.5+DI: 11.0-DI: 5.1

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down28.0
    PSAR$10.79

    Bollinger Bands

    Upper Band$6.95
    Lower Band$3.55
    %B Position6460%(Upper)
    Band Width-0.00

    RSI (14-Day)

    Oversold
    28.4

    Momentum Oscillators

    Stoch %K4.7
    Stoch %D9.4
    Williams %R-92.1
    ROC (10d)-31.7%
    Momentum-1.64
    CCI (20d)-98.6
    MFI (14d)97.7

    Volatility Measures

    ATR (14d)$4.00(113.0%)
    StdDev (20d)0.85
    Hist Vol196.6%(High)

    Volume Flow

    VWAP$3.36
    OBV281.7M
    AD Line508.3B
    CMF (20d)161.484

    Volume Metrics

    Avg Vol (20d)3.3M
    Vol Ratio0.1x(Low)
    VWMA (20d)$6.18

    Pivot Points

    R3$5.90
    R2$5.53
    R1$4.85
    Pivot Point$4.48
    S1$3.80
    S2$3.43
    S3$2.75

    Advanced Oscillators

    TSI-37.22
    Ultimate Osc36.6
    KST-450.99

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$24,245$18,652$21,796$0$0$0$0$0$0$0$0$0
    Cost of Revenue$3,181$4,362$4,231$0$0$0N/A$0$0$0N/A$0
    Gross Profit$21,064$14,290$17,565$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$2.76M$1.98M$2.83M$2.30M$2.26M$1.54M$1.47M$493,547$557,077$570,695$535,642$1.44M
    R&D$600,353$411,049$43,684$816,697$759,448$466,745$201,005$91,911$101,077$98,667$244,730$239,458
    SG&A$2.16M$1.57M$2.78M$1.48M$1.51M$1.07M$1.27M$401,636$456,000$472,028$290,912$1.20M
    Operating Income$-2,742,945$-1,963,000$-2,808,785$-2,297,053$-2,264,880$-1,538,003$-1,469,963$-493,547$-557,077$-570,695$-535,642$-1,442,127
    Interest Income$10,068$18,404$-33,627$10,212$13,050$10,365$5,419$23$53$62$44,329$161
    Interest Expense$90,618$118,644$62,463$1,193$1,135$1,229$970,806$107,382$-895,578$65,756$58,383$298,137
    Income Before Tax$-2,274,397$-2,061,958$-2,575,031$-2,288,034$-2,252,965$-1,528,867$-1,527,627$-591,021$313,123$-634,100$-429,645$-1,774,189
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,274,397$-2,061,958$-2,575,031$-2,288,034$-2,252,965$-1,528,867$-1,527,627$-591,021$313,123$-634,100$-429,645$-1,774,189
    EBITDA$-2,002,705$-1,772,677$-2,285,699$-2,103,811$-2,073,739$-1,348,962$-479,353$-478,622$-577,521$-563,420$-371,262$-1,476,213
    EBIT$-2,193,847$-1,961,718$-2,478,941$-2,297,053$-2,264,880$-1,538,003$-562,240$-483,662$-582,508$-568,406$-535,642$-1,476,213
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JUNS

    News

    Orca Capital AG Discloses 3.3% Passive Stake in Jupiter Neurosciences (NASDAQ: JUNS)

    Orca Capital AG has disclosed a 3.3% passive stake in Jupiter Neurosciences (NASDAQ: JUNS), owning 39,945 common shares. This acquisition is stated to be for passive investment purposes, with no intention to influence the company's control. The ownership percentage is calculated based on 1,220,601 common shares outstanding after Jupiter Neurosciences' registered offering.

    Kalkine Media•8/31/26•
    Somewhat-Bullish

    Jupiter Neurosciences (NASDAQ: JUNS) Faces Nasdaq Capital Market Delisting Over $35M Market-Value Deficiency

    Jupiter Neurosciences (NASDAQ: JUNS) is at risk of delisting from the Nasdaq Capital Market due to its securities failing to meet the $35 million market-value threshold, despite its common stock regaining compliance with the $1.00 per-share minimum bid price. The company intends to appeal Nasdaq's decision, which may delay further action, but the outcome for continued listing remains uncertain. Nasdaq also concluded that Jupiter failed to meet alternative continued-listing standards.

    Kalkine Media•8/31/26•
    Bearish

    Jupiter Neurosciences (NASDAQ: JUNS) raises $2M as Nasdaq review continues

    Jupiter Neurosciences (NASDAQ: JUNS) has raised approximately $2.0 million through a registered direct offering of 307,692 shares at $6.50 per share. The company believes this capital infusion will enable it to meet Nasdaq's $2.5 million stockholders’ equity requirement for continued listing. Nasdaq has not yet issued a formal determination and will continue to monitor JUNS' compliance, with potential delisting if future filings do not show sustained compliance.

    Stock Titan•8/24/26•
    Neutral

    Jupiter Neurosciences Prices $2.0 Million Registered Direct Offering at $6.50 Per Share

    Jupiter Neurosciences announced it has priced a registered direct offering of 307,692 shares at $6.50 per share, aiming to raise approximately $2.0 million in gross proceeds. The closing of this offering is expected around August 24, 2026. The company has also engaged D. Boral Capital as its placement agent for the transaction, agreeing to a 7.0% fee on the gross proceeds.

    TradingView•8/24/26•
    Neutral

    Jupiter Neurosciences (JUNS) starts drawing on $20M equity line after new stock deal

    Jupiter Neurosciences (JUNS) has announced a registered direct offering of 307,692 common shares at $6.50 each, aiming to raise approximately $2.0 million. Concurrently, the company has begun drawing on its $20 million Standby Equity Purchase Agreement with Yorkville, having already issued 107,920 common shares for gross proceeds of $851,194 between August 14 and August 21, 2026. This financial activity supports Jupiter Neurosciences, a clinical-stage biopharmaceutical company focused on central nervous system disorders.

    Stock Titan•8/24/26•
    Neutral

    Frequently Asked Questions About JUNS

    Does JUNS pay dividends?
    Jupiter Neurosciences, Inc. Common Stock (JUNS) does not currently pay a regular dividend.
    What is JUNS's market cap?
    Jupiter Neurosciences, Inc. Common Stock (JUNS) has a market capitalization of $4.67M with a current stock price of $3.54.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In